The Effect of Anti-TNF Therapy on Cardiac Function in Rheumatoid Arthritis: An Observational Study

Milad Baniaamam 1,2,*, M. Louis Handoko 3, Rabia Agca 1,4, Sjoerd C. Heslinga 1,4, Thelma C. Konings 3, Vokko P. van Halm 3 and Mike T. Nurmohamed 1,2,4

1 Amsterdam Rheumatology Immunology Center, Location Reade, 1056 AB Amsterdam, The Netherlands; r.agca@reade.nl (R.A.); s.heslinga@amsterdamumc.nl (S.C.H.); m.nurmohamed@reade.nl (M.T.N.)
2 Amsterdam Cardiovascular Sciences, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands
3 Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands; ml.handoko@amsterdamumc.nl (M.L.H.); t.konings@amsterdamumc.nl (T.C.K.); v.p.vanhalm@amsterdamumc.nl (V.P.v.H.)
4 Department of Rheumatology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands

* Correspondence: m.baniaamam@reade.nl; Tel.: +31-20-242-1808

Received: 7 September 2020; Accepted: 25 September 2020; Published: 29 September 2020

Abstract: Congestive heart failure (CHF) is the second most prevalent cause of death in rheumatoid arthritis (RA). The systemic inflammatory state in RA patients is deemed responsible for this finding. Anti-inflammatory treatment with anti-tumor necrosis factor (anti-TNF) therapy decreases CV risk and subsequently might improve the cardiac function by lowering the overall inflammatory state. This study investigated the effect of anti-TNF on the cardiac function in RA patients. Fifty one RA patients were included, of which thirty three completed follow-up. Included patients were >18 years, had moderate–high disease activity and no history of cardiac disease. Patients were assessed at baseline and after six months of anti-TNF treatment. Patients underwent conventional Speckle tracking and tissue Doppler echocardiography in combination with clinical and laboratory assessments at baseline and follow-up. The left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) showed no changes during follow-up, LVEF 63% (±9) to 62% (±8) \( p = 0.097 \) and GLS −20 (±4) to −20 (±3) \( p = 0.79 \), respectively. Furthermore, E/e’ nor E/A changed significantly between baseline and follow-up, respectively 8 (7–9) and 8 (7–9) \( p = 0.17 \) and 1.1 (±0.4) and 1.1 (±0.4) \( p = 0.94 \). Follow-up NT-proBNP decreased with 23%, from 89 ng/L (47–142) to 69 ng/L (42–155), \( p = 0.10 \). Regression analysis revealed no association between change in inflammatory variables and cardiac function. Echocardiography showed no effect of anti-TNF treatment on the cardiac function in RA patients with low prevalence of cardiac dysfunction. Moreover, NT-proBNP decreased, possibly indicating (subtle) improvement of the cardiac function.

Keywords: rheumatoid arthritis; inflammation; anti-TNF; cardiac function; echocardiography

1. Introduction

Patients with rheumatoid arthritis (RA) have a 1.5-fold increased risk of cardiovascular (CV) mortality [1,2]. The systemic inflammatory state in RA patients is deemed responsible for this increased risk by causing endothelial dysfunction and accelerating atherosclerosis [3,4]. Second after myocardial infarction, congestive heart failure (CHF) is one of the most prevalent causes of death in RA patients [5,6]. The damage caused by a myocardial infarction and formation of subsequent scar tissue might be a cause of the elevated incidence of heart failure. However, a direct effect of the systemic inflammation itself has also been suggested as a cause for the development of left ventricular
LV) dysfunction. The latter is possibly explained by a process in which circulating pro-inflammatory mediators, such as tumor necrosis factor (TNF), induce coronary endothelial activation leading to stiffness of the myocardium and interstitial fibrosis deposition, resulting in impairment of the relaxation of the myocardium (diastolic dysfunction) [7]. Particularly, RA studies have shown an increased prevalence of left ventricular diastolic dysfunction [8–10]. This explanation is underlined by studies demonstrating that the increased incidence of CHF is only partly due to increased prevalence of CV risk factors, such as hypertension, dyslipidemia and increased insulin resistance. However, even after correction for these traditional risk factors, the increased risk for CHF remains [11,12].

Several studies have shown that anti-inflammatory treatment with anti-TNF therapy decreases the CV risk in RA [13–15]. It is plausible that anti-TNF therapy improves the cardiac function by lowering the overall inflammatory state by decreasing coronary endothelial activation and slowing down the process of coronary atherosclerosis [16], thus potentially decreasing the risk of developing CHF in RA patients.

However, previous studies assessing the effect of anti-TNF on the cardiac function have shown conflicting results [17,18]. Firstly, anti-TNF therapy is contra-indicated in (RA) patients with CHF (New York Heart Association class III and IV) [18], following trials from the early '00s suggesting that anti-TNF possibly worsens CHF and increases mortality in non-RA patients with systolic CHF. It must be recognized, however, that the interpretation of these results is still controversial to date [18]. Moreover, several trials did not show a detrimental effect of anti-TNF therapy on the incidence of newly onset CHF in RA patients [19,20]. Two imaging studies assessing the effect of infliximab on the cardiac function with echocardiography showed improved measures of systolic and diastolic function, subsequently an increased left ventricular ejection fraction (LVEF) and a decrease of E/e' (parameter for diastolic function) after at least 3 months treatment, suggesting improvement of the systolic as well as diastolic function [21,22]. Finally, one study investigating the effect of anti-TNF on the cardiac function with Speckle tracking echocardiography did not show improvement of function [23]. Overall, it should be realized that these studies had relatively small sample sizes and altogether, it is presently unknown whether and to what extent TNF blocking therapy has a favorable effect on the cardiac function in patients with RA.

This study aimed to elucidate the effect of anti-inflammatory therapy, i.e., anti-TNF, on the systolic and diastolic cardiac function in RA patients assessed with comprehensive echocardiography (including conventional, tissue-Doppler and Speckle tracking) and cardiac biomarkers.

2. Methods

Study population—a prospective study in fifty one RA patients was performed. Subjects were recruited randomly from a large rheumatology outpatient clinic (Reade) in Amsterdam, the Netherlands and Amsterdam UMC, Vrije Universiteit Amsterdam, department of Rheumatology, the Netherlands from December 2014 and June 2018. All participants gave written informed consent and the protocol (NL49652.048.14) was approved by the medical ethics committee of the Slotervaart hospital and Reade, Amsterdam, the Netherlands. Echocardiography and clinical and laboratory assessments were done at baseline and after 6 months of anti-TNF therapy. Inclusion criteria consisted of patients fulfilling the 1987 ACR criteria for RA [24], being at least 18 years old, having moderate–high disease activity (DAS28 ≥ 3.2) or increased inflammatory biomarkers (i.e., erythrocyte sedimentation rate (ESR) > 15, C-reactive protein (CRP) > 10) and being scheduled for anti-TNF treatment. Patients started subcutaneous treatment with adalimumab (40 mg biweekly), etanercept (50 mg weekly), certolizumab pegol (400 mg biweekly during first two doses followed by 200 mg biweekly) or golimumab (50 mg monthly). Patients with a medical history of cardiac disease such as myocardial infarction and heart failure, and patients who used anti-TNF therapy 3 months prior to start of the study were excluded. Patients were assessed at baseline and after 6 months of anti-TNF treatment.

Clinical assessment—disease activity was assessed by the disease activity score DAS28 [25]. Physical examination included height, weight, blood pressure measurement and joint
examination. Blood sample measurements (non-fasting) included standard hematological assessment, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), triglyceride levels, total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL), NT-proBNP and Troponin-T. All blood samples were assessed in a single laboratory. Health Assessment Questionnaire (HAQ) and patients global assessment of disease activity (VAS). Furthermore, smoking status, history and family history for cardiovascular disease (CVD) were assessed anamnestically.

Echocardiography—transthoracic echocardiography (TTE)—was performed by certified echo technicians at the European Society of Cardiology (ESC)-certified department of echocardiography of the Amsterdam University medical center, location VUmc, using a Philips ultrasound system (Epiq 7 and IE 33, Philips, Amsterdam, NL). All echocardiographic recordings were stored digitally and were afterwards analyzed by an experienced cardiologist specialized in echocardiography (T.C.K.). TTE was performed according to the following protocol based on the guidelines provided by European Association of Echocardiography [26]. Assessment of the cardiac function consisted of apical four-, three- and two-chamber views, and 2D color and spectral flow Doppler recordings. Left ventricular mass (LVM) was computed based on the Devereux and Reichek formula [27]. Pulse wave tissue Doppler imaging was assessed in the apical views to obtain mitral annular velocities. The sample volume was located at, or within 1 cm of the septal (e' sept) and lateral (e' lat) mitral valve insertion sites. Doppler spectral velocity recordings of the mitral inflow were assessed with the sample volume aimed at the tips of mitral valves. From the trans mitral Doppler velocity recordings, the E wave deceleration time (DT), peak E and A velocities and the E/A ratio were acquired. Left atrial volume was obtained using the modified biplane Simpson’s rule. LVEF and diastolic and systolic volumes were computed by Simpson’s from the apical four- and two-chamber view. The left ventricular global longitudinal strain (GLS) was measured using QLab (version 10.3, Philips, Amsterdam, NL) (Figure 1). As the quality of echocardiography is subject to external factors such as excessive fat tissue, not all cardiac parameters were assessed per patient. The total number of cardiac parameter assessments are therefore described per variable in Table 1.

Figure 1. Flowchart of inclusion.
Table 1. Baseline characteristics.

| Patient Characteristics                  | n = 47 |
|------------------------------------------|--------|
| Age, years                               | 57 (±11) |
| Gender, female (n, %)                    | 32 (68%) |
| RA disease duration, years               | 5 (2–19) |
| BMI, kg/m²                                | 26.0 (±4.5) |
| History of vascular disease (n, %)       | 1 (2%) |
| Hypertension (n, %)                      | 4 (9%) |
| Systolic blood pressure, mmHg            | 130 (±15) |
| Diastolic blood pressure, mmHg           | 80 (±10) |
| Hypercholesterolemia (n, %)              | 3 (6%) |
| Diabetes mellitus type 2 (n, %)          | 1 (2%) |
| Smoking (n, %)                            | 13 (29%) |
| Rheumatoid factor positive (n, %)        | 33 (66%) |
| Anti-cyclic citrullinated protein positive (n, %) | 32 (68%) |
| LDL, mmol/L                              | 2.93 (±0.90) |
| HDL, mmol/L                              | 1.57 (±0.50) |

**Medication**

| Current oral corticosteroid use (n, %)   | 13 (28%) |
| Intra-muscular/intra-articular corticosteroid in the past 3 months (n, %) | 9 (19%) |
| csDMARD use                              | 43 (92%) |
| Methotrexate (with or without other csDMARD(s)) | 33 (70%) |
| Other csDMARD(s)                         | 10 (21%) |
| Biological therapy (n, %)                | 16 (34%) |
| Etanercept                               | 23 (49%) |
| Adalimumab                               | 7 (15%) |
| Golimumab                                | 1 (2%) |

**Disease activity parameters**

| DAS28                                     | 4.44 (±1.23) |
| CRP, mmol/L                               | 6.3 (3.1–20.0) |
| ESR, mm/h                                 | 22.5 (9.0–42.5) |
| Health assessment questionnaire (HAQ)     | 1.25 (0.75–1.50) |

**Cardiac parameters**

| E/e' ratio (n = 46)                        | 7.9 (6.6–9.0) |
| E/A ratio (n = 46)                         | 1.1 (±0.36) |
| Deceleration time, ms (n = 43)            | 0.22 (±0.06) |
| LA volume index, mL/m² (n = 33)           | 28.40 (±7.53) |
| LV ejection fraction, % (n = 29)          | 63.1 (±8.8) |
| GLS (n = 44)                              | −19.8 (±3.5) |
| Impaired GLS (>−17%) (n, %) (n = 44)      | 6 (14%) |
| LV mass index, g/m² (n = 42)              | 68.46 (±17.97) |
| Diastolic LV dysfunction (n, %) (n = 46)   | No diastolic dysfunction 38 (83%) |
| grade I                                   | 2 (4%) |
| grade II                                  | 1 (2%) |
| grade III                                 | 0 (0%) |
| indeterminate                             | 5 (11%) |
| Systolic LV dysfunction (n, %) (n = 29)   | 2 (7%) |
| Aortic valve stenosis (n, %) (n = 46)     | 0 (0%) |
| Aortic valve regurgitation (n, %) (n=46)  | 6 (13%) |
| mild                                      | 6 (13%) |
| moderate                                  | 0 (0%) |
| severe                                    | 0 (0%) |
| Mitral valve stenosis (n, %) (n = 46)     | 0 (0%) |
| Mitral valve regurgitation (n, %) (n = 45) | 18 (38%) |
| mild                                      | 18 (38%) |
| moderate                                  | 0 (0%) |
| severe                                    | 0 (0%) |
| H2FPEF score                              | 0 (0%) |
| 0–1 points                                | 32 (70%) |
| 2–4 points                                | 15 (30%) |
| 5–6 points                                | 0 (0%) |

**Cardiac biomarkers**

| Troponin-T, ng/mL                         | 6 (3–8) |
| NT-ProBNP, ng/L                           | 88.6 (47.0–142.0) |

Values are displayed as mean ± standard deviation (SD), median (IQR) or frequencies with corresponding percentages (%). RA = rheumatoid arthritis, BMI = body mass index, LDL = low density lipoprotein, HDL = high density lipoprotein, csDMARD = conventional synthetic Disease Modifying Anti Rheumatic Drug(s), DAS28 = disease activity score-28, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, LA = left atrial, LV = left ventricular, GLS = global longitudinal strain, NT-ProBNP = N-terminal pro hormone-brain natriuretic peptide.
In addition, the modified H2FPEF score was used to calculate the a priori chance of the diastolic dysfunction in this cohort [28]. The peak TRV >2.8 m/s was suggestive for pulmonary hypertension.

Electrocardiography (ECG)—ECGs performed were standard 12-lead ECGs, recorded at 25 mm/s paper speed. ECGs were analyzed by a single investigator (T.C.K.) whom was blinded to the clinical status of all the patients.

Definitions—systolic LV dysfunction was defined as an LVEF <50%. Abnormal GLS was defined as >−17%. Diastolic function assessment was based on the ASE/EACVI 2016 guidelines [29] categorized in 4 grades: normal diastolic function and grade I-III (or indeterminate).

Statistical analysis—characteristics of the population are expressed as ± standard deviation (SD), median (interquartile range) (IQR) or percentages. For comparisons of paired continuous variables between baseline and follow-up with normal distribution, paired student’s t-test was used. In case of non-normal distribution, the Wilcoxon signed-ranks test or log transformation was used. For comparisons of dichotomous variables between baseline and follow-up, the Pearson’s chi-square test was performed. Regression analysis was used to assess the possible effect of change in systemic inflammation on the cardiac function with the follow-up cardiac function parameter as a dependent variable adjusted for the baseline cardiac function parameter, the baseline inflammatory parameter and delta inflammatory parameter (absolute change of the inflammatory variable at follow-up). As inflammatory parameters, the DAS28, CRP and ESR were used. LVEF, GLS, E/e’, E/A and NT-proBNP were used as values for cardiac function.

All analyses were done with SPSS version 23 (SPSS, Chicago, IL, USA) and two-sided p-values less than 0.05 were considered statistically significant.

The sample size was based on the primary outcome, i.e., diastolic LV function as assessed with Doppler echocardiography and was calculated using the McNemar’s test for sample size estimation. With an expected improvement of 25% in diastolic LV function during anti-TNF therapy [23,30] and a significance level of 5% and 90% power, the total calculated sample size was forty four subjects. To account for a loss to follow-up of 10%, fifty one patients were included.

3. Results

3.1. Patient Characteristics

The baseline characteristics are described in Table 1. A total of fifty one subjects participated in the study. Four patients were excluded at baseline for various reasons (no show, suspicion of tuberculosis or cardiac disease de novo, arrhythmia and cardiomyopathy, depicted in Figure 2). The mean age of the patients was 57 (±11) years, of which 68% were female. Median RA disease duration was 5 (2–19) years and disease activity was moderate–high, with a mean DAS28 score of 4.44 (±1.23). Overall, the patient’s mobility was moderately impaired with a median HAQ score of 1.25 (0.75–1.50). One patient had a confirmed vascular event (ischemic CVA) in the history.
with diastolic dysfunction had hypertension nor diabetes mellitus (DM). In comparison, three of the
patients fell out of the follow-up date. DAS28 decreased significantly after six months anti-TNF
therapy, from 4.44 (±1.23) to 2.72 (±1.23), p = 0.001. Furthermore, on average the patients mobility as
scored with the HAQ improved from 1.3 (0.8–1.5) to 0.5 (0.0–1.3), p = 0.001. LVEF and GLS showed no
change after 6 months of anti-TNF therapy, respectively 63.0% (±8.7) to 62.0% (±7.9), p = 0.097 and
−19.8 (±3.5) to -19.9 (±2.6), p = 0.79. See Table 2.

Figure 2. Example of calculation of global longitudinal strain (GLS) by speckle tracking for the apical
four-, three- and two-chamber views (A–C). The strain during one cardiac cycle is shown for each
of the color-coded (red and blue) left ventricular segments. The longitudinal strain bull’s eye plot
(D) determined from 2D speckle tracking imaging offers a visual overview of the regional and global
left ventricular myocardial function in a diagram. In this example of one of the subjects in this study,
the GLS is −27.3%, which is in the normal range.

3.2. Cardiac Function at Baseline

At baseline, three (7%) patients had diastolic LV dysfunction, of which two (4%) had diastolic
dysfunction grade I, and one (2%) had diastolic LV dysfunction grade II. Importantly, two cases of
diastolic dysfunction (grade I) was due to the presence of systolic dysfunction. None of the patients
with diastolic dysfunction had hypertension nor diabetes mellitus (DM). In comparison, three of the
thirty eight (8%) patients with normal diastolic function had hypertension and one (3%) had DM.
Systolic LV dysfunction based on the ejection fraction was seen in two patients (4%). The GLS showed
impaired systolic LV function in six patients (14%).

A total of thirty seven ECGs were assessed of which three ECGs showed abnormalities. These were
a left bundle branch block, a pathologic Q-wave (without a known history of myocardial infarction)
and a first degree atrioventricular block.

3.3. Disease Activity and Cardiac Function at six Months Follow-Up

A total of thirty three patients completed follow-up. Fourteen patients dropped out of which
eight due to treatment failure (lack of efficacy), three participants withdrew out of the study and of
two patients fell out of the follow-up date. DAS28 decreased significantly after six months anti-TNF
therapy, from 4.44 (±1.23) to 2.72 (±1.23), p < 0.001. Furthermore, on average the patients mobility as
scored with the HAQ improved from 1.3 (0.8–1.5) to 0.5 (0.0–1.3), p = 0.001. LVEF and GLS showed no
change after 6 months of anti-TNF therapy, respectively 63.0% (±8.7) to 62.0% (±7.9), p = 0.097 and
−19.8 (±3.5) to -19.9 (±2.6), p = 0.79. See Table 2.
Table 2. Effect of anti-TNF on the cardiac parameters and disease activity parameters.

| Cardiac parameters | Baseline (n = 47) | Follow-Up (n = 33) | p-Value |
|--------------------|-------------------|--------------------|---------|
| E/e’               | 7.9 (6.6–9.0)     | 7.7 (7.1–9.1)      | 0.17    |
| E/A                | 1.1 (±0.4)        | 1.1 (±0.4)         | 0.94    |
| Deceleration time, sec | 0.22 (±0.06)     | 0.22 (±0.04)       | 0.44    |
| LA volume index, mL/m² | 28.4 (±7.5)       | 30.3 (±5.4)        | 0.21    |
| LV ejection fraction, % | 63.0 (±8.7)      | 62.0 (±7.9)        | 0.097   |
| GLS                | −19.8 (±3.5)      | −19.9 (±2.6)       | 0.79    |
| LV mass index, gram/m² | 68.5 (±18.0)     | 73.0 (±22.4)       | 0.66    |
| Troponin-T, µg/mL  | 6 (3–8)           | 7 (4–9)            | 0.43    |
| NT-proBNP, ng/L    | 89 (47–142)       | 69 (42–155)        | 0.10    |

| Disease activity parameters | Baseline | Follow-Up | p-Value |
|-----------------------------|----------|-----------|---------|
| DAS28                        | 4.44 (±1.23) | 2.72 ± 1.23 | <0.001 * |
| CRP, mg/L                   | 6.3 (3.1–20.0) | 2.6 (0.8–7.6) | 0.009 * |
| ESR, mm/h                   | 23 (9.0–43) | 8 (5–15) | <0.001 * |
| HAQ                          | 1.3 (0.8–1.5) | 0.5 (0.0–1.3) | 0.001 * |

Values are displayed as mean ± standard deviation (SD), median (IQR) or frequencies with corresponding percentages (%). LA = left atrial, LV = left ventricular, GLS = global longitudinal strain, NT-proBNP = N-terminal pro hormone-brain natriuretic peptide, DAS28 = disease activity score-28, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, HAQ = health assessment questionnaire. * Significance level of p ≤ 0.05.

From thirty of the thirty three patients with successful follow-up, it was possible to grade the diastolic function. Of these patients, twenty eight had normal diastolic function, one had diastolic dysfunction grade I and one diastolic dysfunction grade II. No patients had diastolic dysfunction grade III. Compared to the baseline, only in one case was the diastolic function changed from normal to grade I. Additionally, neither the E/e’ nor the E/A showed a significant change after six months of anti-TNF therapy, respectively 7.9 (6.6–9.0) to 7.7 (7.1–9.1), p = 0.17 and 1.1 (±0.4) to 1.1 (±0.4), p = 0.94.

NT-proBNP values decreased, although this did not reach statistical significance, with a reduction of 23% at follow-up compared to baseline, respectively 89 ng/L (47–142) to 69 ng/L (42–155, p = 0.10). Troponin-T did not show any change at follow-up, 6 (3–8) µg/mL to 7 (4–9) µg/mL, p = 0.43.

The highest quartile for the LV ventricular filling pressure (E/e’) was compared with the other three quartiles, respectively E/e’ > 9 vs E/e’ < 9. Seven patients had an E/e’ > 9 at baseline who completed follow-up. In these patients, no echocardiographic parameters improved nor worsened after anti-TNF therapy (Table 3).

Table 3. Effect of anti-TNF in patients in the highest E/e’ quartile (E/e’ > 9).

| E/e’ > 9 (n) | Baseline | Follow-Up | p-Value |
|--------------|----------|-----------|---------|
| E/A (6)      | 1.0 (±0.4) | 1.0 (±0.3) | 0.97    |
| E/e’ (7)     | 11.8 (±3.0) | 10.9 (±4.2) | 0.34    |
| deceleration time, sec (4) | 0.23 (±0.06) | 0.26 (±0.05) | 0.34 |
| ejection fraction (4) | 62.0 (±7.4) | 62.2 (±9.5) | 0.97 |
| LV mass index, gram/m² (5) | 83.0 (±26.1) | 100.6 (54.1) | 0.28 |
| LA volume index, mL/m²² (4) | 36.6 (±3.8) | 36.6 (±3.8) | 0.87 |
| GLS (6)      | −18.0 (±3.5) | −18.2 (±2.7) | 0.90    |

Values are displayed as mean ± standard deviation (SD) or median (IQR). LA = left atrial, LV = left ventricular, GLS = global longitudinal strain.
Regression analyses showed no association between changes in inflammatory parameters, i.e., DAS28 and ESR, and changes in cardiac parameters, i.e., $E/\epsilon'$, $E/A$, GLS and NT-proBNP, between baseline and follow-up.

4. Discussion

To our knowledge, this is the first and largest study investigating the effect of first line anti-TNF therapy on the cardiac function in a Western RA cohort assessed with comprehensive echocardiography (including conventional, Speckle tracking and tissue Doppler) in combination with cardiac biomarkers. In contrast to what was expected, the echocardiographic results did not show improvement but importantly also showed no worsening of the cardiac function. Moreover, this study found a 23% decrease of NT-proBNP after six months of anti-TNF therapy, although this did not reach statistical significance.

Overall, diastolic function categorized in grades changed in only one case. The $E/\epsilon'$-ratio, a robust marker for predicting LV filling pressures and indirectly diastolic (dys)function [31], also did not show a significant change at follow-up compared to baseline, not even when comparing the highest quartile with the other quartiles. Examination of the systolic ventricular function was done using the LVEF and the more sensitive GLS to pick up more subtle changes. However, again, no improvement nor deterioration was observed. These unexpected results can be explained by the following causes. First, this could have been due to the low prevalence of cardiac dysfunction at baseline as only three (7%) patients had diastolic dysfunction. Therefore, the study may have been underpowered to show the improvement of the cardiac function. According to the literature, RA patients are more likely to have echocardiographic parameters of diastolic dysfunction in comparison to the general population [8,32,33]. Unexpectedly, our population had a lower-than-expected prevalence of diastolic dysfunction. This is explained because in our study diastolic function was assessed according to the updated 2016 ASE/EACVI grading criteria [29]. This grading algorithm applies several echocardiographic parameters and is more critical than previous grading algorithms of the 2009 ASE/EACVI criteria [34] and the Redfield criteria [35]. The primary goal of the 2016 ASE/EACVI update was to simplify the approach and hence increase the utility of the guidelines in daily clinical practice. However, recent studies also demonstrate a higher specificity and a lower sensitivity of the 2016 ASE/EACVI criteria resulting in a lower overall prevalence of diastolic dysfunction compared to the 2009 ASE/EACVI criteria. In addition, the 2016 ASE/EACVI criteria shows superiority over the 2009 criteria in predicting mortality, myocardial infarction and heart failure [36] and importantly in predicting increased left ventricular pressure measured with invasive assessment [37], thus making it currently the best available non-invasive diastolic dysfunction assessment tool. In comparison, previous studies mostly used the Redfield criteria, which is primary focused on the $E/A$ ratio and the $E$-wave deceleration time (DT). When applying the 2009 ASE/EACVI and Redfield criteria in our cohort, the prevalence of diastolic dysfunction at baseline is considerably higher with respectively fifteen (33%) and eleven patients (23%). However, again, no relevant changes were observed at follow-up.

Second, this population had a relatively short disease duration and a relatively low disease activity compared to other studies, demonstrating an increased prevalence of cardiac dysfunction in RA patients compared to healthy subjects [8,38]. In addition, our population was relatively cardiac healthy as patients were relatively young and had low prevalence of cardiovascular comorbidities, and were thus less prone to the development of cardiac dysfunction. This is also suggested by the low H2FPEF score calculated for this cohort. The H2FPEF score is a method to assess the risk of the presence of heart failure with preserved ejection fraction (HFpEF) in patients with dyspnea and comprises a major risk factor for developing diastolic dysfunction. A large majority of the subjects (94%) had a H2FPEF score ranging from 0–2 and thus, a low a priori chance for diastolic dysfunction. This is also confirmed by the low serum NT-proBNP at baseline, indicating a normal cardiac wall tension. Another possibility could be due to the limitation of echocardiography in the assessment of diastolic function and the lacking ability to detect subtle diastolic changes. Possibly more sensitive
assessment methods, such as exercise echocardiography [39], exercise right heart catheterization [40] or cardiac magnetic resonance imaging (MRI) [41], could help detect mild diastolic dysfunction and subtle diastolic changes. However, GLS analysis, a sensitive assessment method for the systolic dysfunction, did not show any alteration of the cardiac function. Furthermore, a large number of the patients used corticosteroids prior to the start of anti-TNF therapy, thereby affecting the anti-inflammatory effect of anti-TNF. Importantly, we found that anti-TNF therapy had no detrimental effect on the cardiac function in patients with normal and relatively mild cardiac dysfunction.

Interestingly, studies assessing the effect of biologic agents with modes of action other than TNF-blockade show more evident ameliorating effects on the cardiac function. Several studies conducted by Ikonimidos et al. investigating the effect of anti-interleukin (IL)-1 therapy (anakinra) showed a significant improvement in cardiac function assessed with echocardiography [38,42,43]. Studies assessing the effect of anti-IL-6 (tocilizumab) on cardiac function assessed with cardiac MRI also showed an ameliorating effect on the diastolic function [44,45]. A possible explanation for this could be that IL-1 is produced earlier in the cytokine cascade and is the triggering factor of several cytokines including IL-6 and TNF-a [46]. Thus, theoretically, its inhibition may be more effective in controlling inflammation and thus improving LV function than inhibition of the later-released TNF-a. Whether anti-IL-1 and/or anti-IL-6 therapy have indeed more pronounced effects on cardiac function then anti-TNF is not known, as direct comparative studies have not been conducted. NT-proBNP is a predictor of CV mortality and morbidity in patients with or without a history of CVD and RA patients [47–49] and in our study, a 23% NT-pro BNP decrease after 6 months anti-TNF treatment was observed. This is in line with the findings of Kotyla et al., and Peters et al., where infliximab treatment or adalimumab treatment during 4 months led to comparable decreases of serum NT-proBNP in RA patients [22,50]. There are a few explanations for this phenomenon. Firstly, reduction of inflammation could have led to reduced ventricular stress. This is confirmed by the literature describing that inflammation contributes to arterial stiffening and consecutively increases ventricular load [51,52]. Secondly, low grade inflammation of cardiac tissue can lead to a stress response of the myocardium, leading to increased NT-proBNP production. This could explain the overall relationship between NT-proBNP and systemic inflammation [53,54]. However, a direct effect of anti-TNF on the production or secretion of NT-proBNP cannot be ruled out.

A major strength of this study is the comprehensive and prospective approach in the assessment of cardiac function with the use of conventional Doppler and Speckle tracking echocardiography in combination with cardiac biomarkers. Therefore, this study was able to determine the different outcomes assessing the cardiac function. The main limitation of this study was, as the prevalence of cardiac dysfunction was unexpectedly low, the rather limited sample size.

5. Conclusions

In conclusion, echocardiography showed no improvement nor deterioration of anti-TNF treatment on the cardiac function in RA patients with a low prevalence of cardiac dysfunction. However, NT-proBNP decreased 23% after anti-TNF treatment, which might suggest subtle improvement of the cardiac function.

Author Contributions: M.B. recruited and included most participants, analyzed and interpreted the patient data and was a major contributor in writing the manuscript. S.C.H. and R.A. partly recruited and included participants data, substantially contributed to the conception and design of the work and were major contributors in writing the manuscript. M.T.N. substantially contributed to the conception and design of the work, made a major contribution in developing the study protocol and reviewing the manuscript for important intellectual content and acted as leader of the study project. V.P.v.H. and M.L.H. made a major contribution in analyzing and interpreting the patient data and they made a major contribution in reviewing the manuscript for important intellectual content. T.C.K. analyzed all echocardiographic results and made a major contribution in reviewing the manuscript for important intellectual content. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by Pfizer.
Acknowledgments: The authors are grateful to all study participants, as well as the doctors who enrolled patients in this study, all rheumatology nurses involved in patients management, and to Vidya Lall-Enait for the planning and management of all cardiac echos at the Amsterdam UMC, location Vrije Universiteit Amsterdam.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Avina-Zubieta, J.A.; Choi, H.K.; Sadatsafavi, M.; Etminan, M.; Esdaile, J.M.; Lacaille, D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. *Arthritis Rheum.* 2008, 59, 1690–1697. [CrossRef]
2. Maradit-Kremers, H.; Nicola, P.J.; Crowson, C.S.; Ballman, K.V.; Gabriel, S.E. Cardiovascular death in rheumatoid arthritis: A population-based study. *Arthritis Rheum.* 2005, 52, 722–732. [CrossRef]
3. Libby, P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. *Am. J. Med.* 2008, 121 (Suppl. 1), S21–S31. [CrossRef]
4. Crowson, C.S.; Liao, K.P.; Davis, J.M., III; Solomon, D.H.; Matteson, E.L.; Knutson, K.L.; Hlatky, M.A.; Gabriel, S.E. Rheumatoid arthritis and cardiovascular disease. *Am. Heart J.* 2013, 166, 622–628. [CrossRef]
5. Mok, C.C.; Kwok, C.L.; Ho, L.Y.; Chan, P.T.; Yip, S.F. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. *Arthritis Rheum.* 2011, 63, 1182–1189. [CrossRef]
6. Turesson, C.; Jarenros, A.; Jacobsson, L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: Results from a community based study. *Ann. Rheum Dis.* 2004, 63, 952–955. [CrossRef]
7. Paulus, W.J.; Tschope, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J. Am. Coll. Cardiol.* 2013, 62, 263–271. [CrossRef] [PubMed]
8. Aslam, F.; Bandeali, S.J.; Khan, N.A.; Alam, M. Diastolic dysfunction in rheumatoid arthritis: A meta-analysis and systematic review. *Arthritis Care Res.* 2013, 65, 534–543. [CrossRef] [PubMed]
9. Renjith, A.S.; Marwaha, V.; Aggarwal, N.; Koshy, V.; Singal, V.K.; Kumar, K. Prevalence of left ventricular dysfunction in rheumatoid arthritis. *J. Fam. Med. Prim. Care* 2017, 6, 622–626.
10. Giles, J.T.; Fernandes, V.; Lima, J.A.; Bathon, J.M. Myocardial dysfunction in rheumatoid arthritis: Epidemiology and pathogenesis. *Arthritis Res. Ther.* 2005, 7, 195–207. [CrossRef] [PubMed]
11. Mantel, A.; Holmqvist, M.; Andersson, D.C.; Lund, L.H.; Askling, J. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. *J. Am. Coll. Cardiol.* 2017, 69, 1275–1285. [CrossRef] [PubMed]
12. Nicola, P.J.; Maradit-Kremers, H.; Roger, V.L.; Jacobsen, S.J.; Crowson, C.S.; Ballman, K.V.; Gabriel, S.E. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. *Arthritis Rheum.* 2005, 52, 412–420. [CrossRef] [PubMed]
13. van Halm, V.P.; Nurmohamed, M.T.; Twisk, J.W.; Dijkmans, B.A.; Voskuyl, A.E. Disease-modifying antiinflammatory drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. *Arthritis Res. Ther.* 2006, 8, R151. [CrossRef] [PubMed]
14. Westlake, S.L.; Colebatch, A.N.; Baird, J.; Curzen, N.; Kiely, P.; Quinn, M.; Choy, E.; Ostor, A.J.; Edwards, C.J. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. *Rheumatology* 2011, 50, 518–531. [CrossRef] [PubMed]
15. van Sijl, A.M.; van Eijk, I.C.; Peters, M.J.; Serne, E.H.; van der Horst-Bruinsma, I.E.; Smulders, Y.M.; Nurmohamed, M.T. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. *Ann. Rheum. Dis.* 2015, 74, 119–123. [CrossRef]
16. van Sijl, A.; Mamas, M.; Lunt, M.; Watson, K.; Symmons, D.P.; Hyrich, K.L. Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Arthritis Rheumatol.* 2014, 66, S840.
17. Banjaamam, M.; Paulus, W.J.; Blanken, A.B.; Nurmohamed, M.T. The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: A systematic review. *Expert Opin. Biol. Ther.* 2018, 18, 585–594. [CrossRef]
18. Anker, S.D.; Coats, A.J.S. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. *Int. J. Cardiol.* 2002, 86, 123–130. [CrossRef]
19. Listing, J.; Strangfeld, A.; Kekow, J.; Schneider, M.; Kapelle, A.; Wassenberg, S.; Zink, A. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? *Arthritis Rheum.* 2008, 58, 667–677. [CrossRef]
20. Al-Aly, Z.; Fan, H.; Zeringue, A.; Xian, H.; McDonald, J.R.; El-Achkar, T.M.; Eisen, S. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. *Transl. Res.* 2011, 157, 10–18. [CrossRef]
21. Kotyla, P.J.; Owczarek, A.; Rakoczy, J.; Lewicki, M.; Kucharz, E.J.; Emery, P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis. *J. Rheumatol.* 2014, 25, 168–175. [PubMed]
22. Cetin, S.; Mustafa, G.; Keskin, G.; Yeter, E.; Dogan, M.; Ozturk, M.A. Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: Preliminary results. *Cardiovasc. J. Afr.* 2012, 2015, 2016, 2017, 2018, 2019, 2020.
23. Vizzardi, E.; Cavazzana, I.; Franceschini, F.; Bonadei, I.; Sciatti, E.; Lombardi, C.M.; Tincani, A.; Metra, M. Left ventricular function in rheumatoid arthritis during anti-TNF-alpha treatment: A speckle tracking prospective echocardiographic study. *Monaldi Arch. Chest Dis.* 2016, 84, 716. [CrossRef] [PubMed]
24. Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988, 31, 315–324. [CrossRef] [PubMed]
25. Prevoo, M.L.; Van’t Hof, M.A.; Kuper, H.H.; Van Leeuwen, M.A.; Van De Putte, L.B.; Van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995, 38, 44–48. [CrossRef]
26. Lang, R.M.; Badano, L.P.; Tsang, W.; Adams, D.H.; Agricola, E.; Buck, T.; Faletra, F.E.; Franke, A.; Hung, J.; de Isla, L.P.; et al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. *Eur. Heart J. Cardiovasc. Imaging.* 2012, 13, 1–46. [CrossRef]
27. Devereux, R.B.; Reichek, N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. *Circulation* 1977, 55, 613–618. [CrossRef]
28. Reddy, Y.N.V.; Carter, R.E.; Obokata, M.; Redfield, M.M.; Borlaug, B.A. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction. *Circulation* 2018, 138, 861–870. [CrossRef]
29. Nagueh, S.F.; Smiseth, O.A.; Appleton, C.P.; Byrd, B.F., III; Dokainish, H.; Edvardsen, T.; Flachskampf, F.A.; Gillebert, T.C.; Klein, A.L.; Lancellotti, P.; et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J. Am. Soc. Echocardiogr.* 2016, 29, 277–314. [CrossRef]
30. Tomas, L.; Lazurova, I.; Sundalova, L.; Zuckovic, M.; Petrasova, D.; Studenican, M. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. *Clin. Rheumatol.* 2013, 32, 61–66. [CrossRef]
31. Nauta, J.F.; Hummel, Y.M.; van der Meer, P.; Lam, C.S.P.; Voors, A.A.; van Melle, J.P. Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: A systematic review in patients with heart failure with preserved ejection fraction. *Eur. J. Heart Fail.* 2018, 20, 1303–1311. [PubMed]
32. Sharma, A.; Kaushik, R.; Kaushik, R.M.; Kakkar, R. Echocardiographic evaluation of diastolic dysfunction in rheumatoid arthritis—A case-control study. *Mod. Rheumatol.* 2015, 25, 552–557. [CrossRef] [PubMed]
33. Targonska-Stepniak, B.; Biskup, M.; Biskup, W.; Majdan, M. Diastolic dysfunction in rheumatoid arthritis patients with low disease activity. *Clin. Rheumatol.* 2019, 38, 1131–1137. [CrossRef] [PubMed]
34. Almeida, J.G.; Fonseca-Chaves, R.; Sampaio, F.; Ribeiro, J.; Bettencourt, P.; Flachskampf, F.A.; Leite-Moreira, A.; Azevedo, M. Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population. *Eur. Heart J. Cardiovasc. Imaging* 2018, 19, 380–386. [CrossRef] [PubMed]
35. Redfield, M.M.; Jacobsen, S.J.; Burnett, J.C., Jr; Mahoney, D.W.; Bailey, K.R.; Rodeheffer, R.J. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. *JAMA* 2003, 289, 194–202. [CrossRef]
36. Prasad, S.B.; Holland, D.J.; Atherton, J.J.; Whalley, G. New Diastology Guidelines: Evolution, Validation and Impact on Clinical Practice. *Heart Lung Circ.* 2019, 28, 1411–1420. [CrossRef]
37. Balaney, B.; Medvedofsky, D.; Mediratta, A.; Singh, A.; Ciszek, B.; Kruse, E.; Shah, A.P.; Addetia, K.; Lang, R.M.; Mor-Avi, V. Invasive Validation of the Echocardiographic Assessment of Left Ventricular Filling Pressures Using the 2016 Diastolic Guidelines: Head-to-Head Comparison with the 2009 Guidelines. *J. Am. Soc. Echocardiogr.* 2018, 31, 79–88. [CrossRef]
38. Ikonomidis, I.; Tzortzis, S.; Andreadou, I.; Paraskevaidis, I.; Katseli, C.; Katsimbri, P.; Pavlidis, G.; Parissis, J.; Kremastinos, D.; Anastasiou-Nana, M.; et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. *Circ. Cardiovasc. Imaging* 2014, 7, 619–628. [CrossRef]
39. Obokata, M.; Kane, G.C.; Reddy, Y.N.; Olson, T.P.; Melenovsky, V.; Borlaug, B.A. Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. *Circulation* 2017, 135, 825–838. [CrossRef]
40. Huis In’t Veld, A.E.; de Man, F.S.; van Rossum, A.C.; Handoko, M.L. How to diagnose heart failure with preserved ejection fraction: The value of invasive stress testing. *Neth. Heart J.* 2016, 24, 244–251. [CrossRef]
41. Chamsi-Pasha, M.A.; Zhan, Y.; Debs, D.; Shah, A.P. CMR in the Evaluation of Diastolic Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives. *JACC Cardiovasc. Imaging* 2020, 13 (1 Pt 2), 283–296. [CrossRef]
42. Ikonomidis, I.; Lekakis, J.P.; Nikolaou, M.; Paraskevaidis, I.; Andreadou, I.; Kaplanoglou, T.; Katsimbri, P.; Skarantavos, G.; Soucacos, P.N.; Kremastinos, D.T. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. *Circulation* 2008, 117, 2662–2669. [CrossRef] [PubMed]
43. Ikonomidis, I.; Tzortzis, S.; Lekakis, J.; Paraskevaidis, I.; Andreadou, I.; Nikolaou, M.; Kaplanoglou, T.; Katsimbri, P.; Skarantavos, G.; Soucacos, P.; et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. *Heart* 2009, 95, 1502–1507. [CrossRef] [PubMed]
44. Kobayashi, H.; Kobayashi, Y.; Giles, J.T.; Yoneyama, K.; Nakajima, Y.; Takei, M. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: Assessed using 3.0 tesla cardiac magnetic resonance imaging. *J. Rheumatol.* 2014, 41, 1916–1921. [CrossRef] [PubMed]
45. Kobayashi, Y.; Kobayashi, H.; Giles, J.T.; Hirano, M.; Nakajima, Y.; Takei, M. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. *Int. J. Rheum. Dis.* 2016, 19, 1169–1174. [CrossRef] [PubMed]
46. Schiff, M.H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. *Ann. Rheum. Dis.* 2000, 59 (Suppl. 1), i103–i108. [CrossRef] [PubMed]
47. Natriuretic Peptides Studies, C.; Willeit, P.; Kaptoge, S.; Welsh, P.; Butterworth, A.S.; Chowdhury, R.; Spackman, S.A.; Pennells, L.; Gao, P.; Burgess, S.; et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol.* 2016, 4, 840–849.
48. Di Angelantonio, E.; Chowdhury, R.; Sarwar, N.; Ray, K.K.; Gobin, R.; Saleheen, D.; Thompson, A.; Gudnason, V.; Sattar, N.; Danesh, J. B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. *Circulation* 2009, 120, 2177–2187. [CrossRef]
49. Provan, S.; Angel, K.; Semb, A.G.; Atar, D.; Kviens, T.K. NT-proBNP predicts mortality in patients with rheumatoid arthritis: Results from 10-year follow-up of the EURIDISS study. *Ann. Rheum. Dis.* 2010, 69, 1946–1950. [CrossRef]
50. Peters, M.J.; Welsh, P.; McInnes, I.B.; Wolbink, G.; Dijkmans, B.A.; Sattar, N.; Nurmohamed, M.T. Tumour necrosis factor α blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: Results from a prospective cohort study. *Ann. Rheum. Dis.* 2010, 69, 1281–1285. [CrossRef]
51. Jain, S.; Khera, R.; Corrales-Medina, V.F.; Townsend, R.R.; Chirinos, J.A. Inflammation and arterial stiffness in humans. *Atherosclerosis* 2014, 237, 381–390. [CrossRef]
52. Vlachopoulos, C.; Dima, I.; Aznaouridis, K.; Vasiiliadou, C.; Ioakeimidis, N.; Aggeli, C.; Toutouza, M.; Stefanadis, C. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. *Circulation* 2005, 112, 2193–2200. [CrossRef] [PubMed]

53. Giannoni, A.; Tani, C.; Clerico, A.; Passino, C.; Tavoni, A.; d’Ascanio, A.; Bombardieri, S.; Emdin, M. When the heart is burning: Amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. *Int. J. Cardiol.* 2011, 148, 161–167. [CrossRef] [PubMed]

54. Moraes, J.C.; Ribeiro, A.C.; Saad, C.G.; Lianza, A.C.; Silva, C.A.; Bonfa, E. NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: A pilot study. *Clin. Rheumatol.* 2013, 32, 879–883. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).